|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC18 |
Gene summary for CCDC18 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC18 | Gene ID | 343099 |
| Gene name | coiled-coil domain containing 18 | |
| Gene Alias | NY-SAR-41 | |
| Cytomap | 1p22.1 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q5T9S5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 343099 | CCDC18 | P2T-E | Human | Esophagus | ESCC | 2.76e-12 | 2.94e-01 | 0.1177 |
| 343099 | CCDC18 | P4T-E | Human | Esophagus | ESCC | 6.07e-05 | 1.48e-01 | 0.1323 |
| 343099 | CCDC18 | P5T-E | Human | Esophagus | ESCC | 1.10e-10 | 2.61e-01 | 0.1327 |
| 343099 | CCDC18 | P8T-E | Human | Esophagus | ESCC | 3.79e-03 | 1.04e-01 | 0.0889 |
| 343099 | CCDC18 | P9T-E | Human | Esophagus | ESCC | 2.34e-05 | 1.27e-01 | 0.1131 |
| 343099 | CCDC18 | P10T-E | Human | Esophagus | ESCC | 7.09e-09 | 2.93e-01 | 0.116 |
| 343099 | CCDC18 | P12T-E | Human | Esophagus | ESCC | 2.23e-46 | 9.05e-01 | 0.1122 |
| 343099 | CCDC18 | P16T-E | Human | Esophagus | ESCC | 4.40e-09 | 1.39e-01 | 0.1153 |
| 343099 | CCDC18 | P20T-E | Human | Esophagus | ESCC | 2.57e-04 | 2.17e-01 | 0.1124 |
| 343099 | CCDC18 | P21T-E | Human | Esophagus | ESCC | 1.91e-03 | 1.58e-01 | 0.1617 |
| 343099 | CCDC18 | P22T-E | Human | Esophagus | ESCC | 1.50e-06 | 1.04e-01 | 0.1236 |
| 343099 | CCDC18 | P23T-E | Human | Esophagus | ESCC | 7.20e-03 | 2.06e-01 | 0.108 |
| 343099 | CCDC18 | P26T-E | Human | Esophagus | ESCC | 3.25e-04 | 1.31e-01 | 0.1276 |
| 343099 | CCDC18 | P27T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.58e-01 | 0.1055 |
| 343099 | CCDC18 | P28T-E | Human | Esophagus | ESCC | 2.18e-16 | 3.73e-01 | 0.1149 |
| 343099 | CCDC18 | P30T-E | Human | Esophagus | ESCC | 3.78e-03 | 2.66e-01 | 0.137 |
| 343099 | CCDC18 | P31T-E | Human | Esophagus | ESCC | 2.92e-10 | 2.57e-01 | 0.1251 |
| 343099 | CCDC18 | P32T-E | Human | Esophagus | ESCC | 1.07e-09 | 2.46e-01 | 0.1666 |
| 343099 | CCDC18 | P47T-E | Human | Esophagus | ESCC | 3.18e-02 | 9.38e-02 | 0.1067 |
| 343099 | CCDC18 | P48T-E | Human | Esophagus | ESCC | 8.79e-04 | 1.39e-01 | 0.0959 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00995185 | Esophagus | ESCC | vesicle cytoskeletal trafficking | 50/8552 | 73/18723 | 6.75e-05 | 5.12e-04 | 50 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:0009743111 | Esophagus | ESCC | response to carbohydrate | 135/8552 | 253/18723 | 8.16e-03 | 2.89e-02 | 135 |
| GO:00097437 | Liver | NAFLD | response to carbohydrate | 45/1882 | 253/18723 | 1.07e-04 | 2.11e-03 | 45 |
| GO:00425936 | Liver | NAFLD | glucose homeostasis | 45/1882 | 258/18723 | 1.71e-04 | 3.08e-03 | 45 |
| GO:00335006 | Liver | NAFLD | carbohydrate homeostasis | 45/1882 | 259/18723 | 1.87e-04 | 3.29e-03 | 45 |
| GO:00342847 | Liver | NAFLD | response to monosaccharide | 37/1882 | 225/18723 | 1.86e-03 | 1.91e-02 | 37 |
| GO:00307055 | Liver | NAFLD | cytoskeleton-dependent intracellular transport | 33/1882 | 195/18723 | 1.98e-03 | 1.98e-02 | 33 |
| GO:00097467 | Liver | NAFLD | response to hexose | 36/1882 | 219/18723 | 2.14e-03 | 2.08e-02 | 36 |
| GO:00516565 | Liver | NAFLD | establishment of organelle localization | 57/1882 | 390/18723 | 2.52e-03 | 2.34e-02 | 57 |
| GO:00516485 | Liver | NAFLD | vesicle localization | 30/1882 | 177/18723 | 3.01e-03 | 2.72e-02 | 30 |
| GO:00355926 | Liver | NAFLD | establishment of protein localization to extracellular region | 52/1882 | 360/18723 | 4.80e-03 | 3.81e-02 | 52 |
| GO:00516505 | Liver | NAFLD | establishment of vesicle localization | 27/1882 | 161/18723 | 5.47e-03 | 4.20e-02 | 27 |
| GO:00016786 | Liver | NAFLD | cellular glucose homeostasis | 28/1882 | 172/18723 | 7.15e-03 | 4.96e-02 | 28 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC18 | SNV | Missense_Mutation | novel | c.873T>G | p.Cys291Trp | p.C291W | Q5T9S5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| CCDC18 | SNV | Missense_Mutation | c.3733N>G | p.Gln1245Glu | p.Q1245E | Q5T9S5 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-GM-A2DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
| CCDC18 | insertion | Frame_Shift_Ins | novel | c.4356_4357insT | p.Asn1453Ter | p.N1453* | Q5T9S5 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCDC18 | insertion | Nonsense_Mutation | novel | c.4358_4359insCAGATAGAATAATTTCTTACTCTGTAGGT | p.Val1454ArgfsTer2 | p.V1454Rfs*2 | Q5T9S5 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCDC18 | deletion | Frame_Shift_Del | c.2939delN | p.Lys981AsnfsTer5 | p.K981Nfs*5 | Q5T9S5 | protein_coding | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| CCDC18 | SNV | Missense_Mutation | novel | c.2661A>G | p.Ile887Met | p.I887M | Q5T9S5 | protein_coding | deleterious(0.01) | possibly_damaging(0.592) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCDC18 | SNV | Missense_Mutation | novel | c.97N>A | p.Glu33Lys | p.E33K | Q5T9S5 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-C5-A1MF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC18 | SNV | Missense_Mutation | novel | c.2991N>T | p.Met997Ile | p.M997I | Q5T9S5 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-C5-A1MF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC18 | SNV | Missense_Mutation | novel | c.3727N>A | p.Asp1243Asn | p.D1243N | Q5T9S5 | protein_coding | deleterious(0.02) | benign(0.429) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| CCDC18 | SNV | Missense_Mutation | novel | c.1219N>A | p.Glu407Lys | p.E407K | Q5T9S5 | protein_coding | tolerated(0.28) | benign(0.23) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |